Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ledaborbactam SCHEMBL17337620 | 1.00 | MTNR1A (0.40) | MTNR1AMTNR1BCYP1A2ALOX15MAPT | |
| SCHEMBL17337118 | 0.91 | MTNR1A (0.42) | MTNR1AMTNR1BMEN1KMT2APARP1 | |
| SCHEMBL17337121 | 0.91 | MTNR1A (0.42) | MTNR1AMTNR1BMEN1KMT2APARP1 | |
| SCHEMBL12944904 | 0.89 | PARP1 (0.34) | MTNR1AMTNR1BCYP1A2ALOX15MAPT | |
| SCHEMBL17286480 | 0.89 | PARP1 (0.33) | PARP1 | |
| SCHEMBL22474794 | 0.89 | PARP1 (0.33) | PARP1 | |
| SCHEMBL15861561 | 0.88 | KMT2A (0.40) | KMT2APARP1 | |
| SCHEMBL17336976 | 0.88 | MTNR1A (0.41) | MTNR1AMTNR1BCYP1A2ALOX15MAPT | |
| SCHEMBL15861559 | 0.88 | KMT2A (0.40) | KMT2APARP1 | |
| SCHEMBL17336977 | 0.88 | MTNR1A (0.41) | MTNR1AMTNR1BCYP1A2ALOX15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544395-B2 | Combination compositions comprising a beta-lactamase inhibitor and uses thereof | VenatoRx Pharmaceuticals, Inc. (US) | 2026-02-10 | — | — | US | claimed |
| US-20220125812-A1 | COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-28 | — | — | US | claimed |
| US-20260146052-A1 | CITRATE COORDINATION COMPLEX OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF | VenatoRx Pharmaceuticals, Inc. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12559509-B1 | Citrate coordination complex of an orally-delivered beta-lactamase inhibitor and uses thereof | VenatoRx Pharmaceuticals, Inc. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12544395-B2 | Combination compositions comprising a beta-lactamase inhibitor and uses thereof | VenatoRx Pharmaceuticals, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-3886798-B1 | COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF | VENATORX PHARMACEUTICALS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-3882252-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025111328-A1 | CITRATE COORDINATION COMPLEX OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF | VenatoRx Pharmaceuticals, Inc. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20220194964-A1 | SOLID FORMS OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2022-06-23 | — | — | US | disclosed |
| US-20220194964-A1 | SOLID FORMS OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2022-06-23 | — | — | US | disclosed |
| US-20220125812-A1 | COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-28 | — | — | US | disclosed |
| US-20170342092-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-30 | — | — | US | disclosed |
| US-9783555-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170226135-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-10 | — | — | US | disclosed |
| US-20170226135-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-10 | — | — | US | disclosed |
| WO-2017100537-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-06-15 | — | — | WO | disclosed |
| US-9637504-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-3154989-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20160264598-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
| WO-2015191907-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125812-A1 | COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF | BCHE, LCT, BPGM | MTNR1A 3322/4885MTNR1B 1789/4885CYP1A2 402/4885 |
| US-20170342092-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | MTNR1A 3641/4885MTNR1B 3337/4885CYP1A2 510/4885 |
| US-20220194964-A1 | SOLID FORMS OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF | SI, MGAM, CEL | MTNR1A 4006/4885MTNR1B 2607/4885CYP1A2 446/4885 |
| US-20260146052-A1 | CITRATE COORDINATION COMPLEX OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF | CMBL, SLC10A1, CLIC1 | MTNR1A 4633/4885MTNR1B 4239/4885CYP1A2 1556/4885 |
| US-12559509-B1 | Citrate coordination complex of an orally-delivered beta-lactamase inhibitor and uses thereof | CMBL, CPN1, BPHL | MTNR1A 4727/4885MTNR1B 4369/4885CYP1A2 1355/4885 |
| US-12544395-B2 | Combination compositions comprising a beta-lactamase inhibitor and uses thereof | LCT, CTRC, CPN1 | MTNR1A 2917/4885MTNR1B 2109/4885CYP1A2 348/4885 |
| US-20170226135-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | MTNR1A 3641/4885MTNR1B 3337/4885CYP1A2 510/4885 |
| US-20160264598-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | MTNR1A 3641/4885MTNR1B 3337/4885CYP1A2 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.